Chien‐Feng Chen

Topological control of cytokine receptor signaling induces differential effects in hematopoiesis

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

Platelets and the immune continuum

Lineage-Specific Hematopoietic Growth Factors

AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management

Immune thrombocytopenic purpura in adults

Protein therapeutics: a summary and pharmacological classification

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

The pathogenesis of immune thrombocytopaenic purpura

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal

How I treat idiopathic thrombocytopenic purpura (ITP)

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpura

Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura.

Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP).